Top

Aurobindo gets observations from FDA for Hyderabad facility

Aurobindo gets observations from FDA for Hyderabad facility
Highlights

Aurobindo Pharma Ltd on Wednesday said that it has received an establishment inspection report from the US health regulator with Voluntary Action...

Hyderabad: Aurobindo Pharma Ltd on Wednesday said that it has received an establishment inspection report from the US health regulator with Voluntary Action Initiated (VAl) status for its Unit VIII manufacturing facility in Hyderabad.

"Further to our intimation dated November 6, 2019 with regard to the USFDA inspection of Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad, we would like to inform that the company has received the Establishment Inspection Report (EIR) with VAl status from the USFDA," the drug firm said.

USFDA issues an EIR to the company when an inspection is satisfactorily closed.

Show Full Article
Print Article

Download The Hans India Android App or iOS App for the Latest update on your phone.
Subscribed Failed...
Subscribed Successfully...
Next Story
More Stories